Introduction {#S0001}
============

Epilepsy is the most common serious neurological condition in the world, with an estimated prevalence of 1% of the population^\[[@CIT0001]\]^. Traditional epilepsy management includes pharmacological treatment, epilepsy surgery, and vagal nerve stimulation. Despite these therapies, 25% of children continue to have uncontrolled seizures. The ketogenic diet (KD), which has been in use since 1921, is a treatment option for many of these epilepsy patients. Ketogenic diet is high in fat, moderate in protein and low in carbohydrates. This combination of energy results in a sustained ketosis that somehow serves to abate seizures through an unknown mechanism. In the following years, with the use of anti-epileptic drugs such as phenytoinum natricum, ketogenic diet is not widely used in epilepsy treatment. While in the recent years, with the increase of drug resistance and adverse effect of anti-epileptic drugs, ketogenic diet was newly considered and promoted in epilepsy treatment. Recently, A review suggests that in children, the ketogenic diet results in short to medium term benefits in seizure control, the effects of which are comparable to modern antiepileptic drugs^\[[@CIT0002]\]^.

In this article, existing studies (retrospective studies and prospective studies) were collected and used to systematically evaluate therapeutic success of ketogenic diet at different duration. Individual studies were summarized using meta- analysis of generic inverse variance method.

Subjects and Methods {#S0002}
====================

Search Strategy and Selection Criteria {#S20003}
--------------------------------------

As the basis for our analysis, we performed a MEDLINE search of the literature from 2000 to December 2011. The search themes were combined as "(ketogenic diet or ketosis or ketone) and (epilepsy seizures or focal seizures or seizures or epilepsy or refractory seizures or generalized seizures)". In addition, we performed a Google Scholar search.

Two investigators independently reviewed titles and abstracts, and selected articles addressing ketogenic diet and epilepsy. Disagreements were resolved by discussion and consensus. On a second sift, we selected original studies on ketogenic diet and epilepsy with the following inclusion criteria:Addressing ketogenic diet and epilepsy.The study should provide sample size.The study should provide the percentage of seizure reduction with the corresponding ketogenic diet duration.KD type including johns Hopkins protocol, modified Atkins diet, classical ketogenic diet.

Definitions {#S20004}
-----------

For the purpose of meta-analysis, therapeutic success was defined as ≥50% seizure reduction at follow-up.

Data Extraction and Analysis {#S20005}
----------------------------

For each study included, the full text was retrieved and the following data were extracted: authors, year of publication, size, gender and mean (or range) of age of the sample, and ketogenic diet duration. For each included study, we extracted the percentage of seizure reduction with the corresponding ketogenic diet duration.

Two investigators performed the extraction of the data in duplicate to avoid errors. The percentage of seizure free, \>90% decrease, \>50% decrease were always selected when available; otherwise the number of seizure free, \>90% decrease, \>50% decrease were recorded. We pooled studies that present percentages or the subjects that could be defined as therapeutic success.

Given the high number of potential ketogenic diet duration, we restricted our analysis to those for which the therapeutic success was assessed by at least 3 studies. Therapeutic success was analyzed separately according to the duration of ketogenic diet.

We used SAS (r) Software 9.2 to analyze data. The statistical heterogeneity of the included studies was assessed by using the χ^2^ test and the I^2^ index. The latter examines the percentage of total variation across studies that are due to heterogeneity between studies rather than by randomness. A value of I^2^ greater than about 70% indicates a high level of heterogeneity. Since the results showed no statistical heterogeneity, we estimated therapeutic success rate for ketogenic diet as a treatment option for epilepsy and its 95% confidence interval (95%) CIs using generic inverse variance method^\[[@CIT0003]\]^. Using generic inverse variance method, each study estimate of the success rate is given a weight that is equal to the inverse of the variance of the effect estimate.

Findings {#S0006}
========

The MEDLINE search produced 933 citations. Records after duplicates removed resulted in 933 citations. Review of titles and abstracts resulted in the selection of 55 articles, among which 38 articles met the inclusion criteria. Selected characteristics of the 38 included articles are reported individually in [Table 1](#T0001){ref-type="table"}, ^\[[@CIT0004]--[@CIT0041]\]^.

###### 

Summary of 38 studies investigating ketogenic diet and epilepsy

  Study   Author, Reference        Prospective/ Retrospective   Year   Sample Size Number   Male   Median /Mean/Range Age of Study Population (years)
  ------- ------------------------ ---------------------------- ------ -------------------- ------ ----------------------------------------------------
  1       **Roberto, et al**       Prospective                  2011   24                   16     6 \[mean\]
  2       **Mara, et al**          Prospective                  2011   18                   9      29 \[median\]
  3       **Maria, et al**         Prospective                  2010   50                   23     4.6 \[mean\]
  3       **Maria, et al**         Prospective                  2010   33                   15     8.25 \[mean\]
  4       **Yoon, et al**          Retrospectively              2011   20                   12     6.9 \[mean\]
  5       **Rima, et al**          Prospective                  2011   15                   NR     5 \[mean\]
  6       **Amnon, et al**         Prospective                  2009   9                    2      28 \[mean\]
  7       **Pavel, et al**         Prospective                  2010   12                   4      24--65 \[range\]
  8       **Eric, et al**          Prospective                  2010   5                    3      4--18 \[range\]
  9       **Eric**                 Prospective                  2011   30                   11     7 \[mean\]
  10      **Dekker**               Retrospective                2010   43                   NR     2--19 \[range\]
  11      **Amanda**               Prospective                  2010   104                  59     1.2 \[mean\]
  12      **Beniczky**             Retrospective                2010   50                   27     1--14.5 \[range\]
  13      **Anastasia, et al**     Retrospective                2010   50                   22     4.5 \[mean\]
  14      **Giangennaro, et al**   Prospective                  2009   38                   22     3.1 \[mean\]
  15      **Suvasini, et al**      Prospective                  2009   27                   NR     2.5 \[mean\]
  16      **Natacha, et al**       Retrospective                2009   17                   NR     2.7 \[mean\]
  16      **Natacha, et al**       Retrospective                2009   10                   NR     6.4 \[mean\]
  17      **John, et al**          Prospective                  2009   20                   NR     1--10 \[range\]
  18      **Elizabeth, et al**     Prospective                  2008   73                   40     2--16 \[range\]
  19      **Eric**                 Retrospective                2008   13                   6      NR
  19      **Eric, et al**          Retrospective                2008   20                   13     NR
  20      **Eric, et al**          Prospective                  2007   30                   11     31 \[mean\]
  21      **Eric, et al**          Prospective                  2007   10                   6      4--25 \[range\]
  21      **Eric, et al**          Prospective                  2007   10                   4      3--16 \[range\]
  22      **Joo, et al**           Prospective                  2007   40                   24     4.3 \[mean\]
  22      **Joo, et al**           Prospective                  2007   36                   19     3.7 \[mean\]
  23      **Hoon-Chul, et al**     Prospective                  2007   14                   NR     7.4 \[mean\]
  24      **So-Hee, et al**        Retrospective                2006   43                   24     1.6 \[mean\]
  25      **Eric, et al**          Prospective                  2006   20                   9      8.1 \[mean\]
  26      **Elisabeth, et al**     Prospective                  2006   150                  85     5.3 \[mean\]
  27      **Christina,et al**      Prospective                  2005   24                   17     5.8 \[mean\]
  27      **Christina,et al**      Prospective                  2006   24                   17     4.8 \[mean\]
  28      **Mark, et al**          Retrospective                2005   26                   6      6.1 \[mean\]
  29      **Hoon-Chul, et al**     Retrospective                2005   199                  110    4.8 \[mean\]
  30      **Seyed, et al**         Prospective                  2010   24                   NR     1--16 \[range\]
  31      **Giangennaro, et al**   Prospective                  2002   56                   36     10.4 \[mean\]
  32      **Bernhard, et al**      Retrospective                2001   134                  NR     7.5 \[mean\]
  33      **Cheryl, et al**        Prospective                  2001   150                  NR     NR
  34      **Mackenzie, et al**     Retrospective                2003   45                   25     14.4 \[mean\]
  35      **James, et al**         Retrospective                2005   10                   10     0.5 \[mean\]
  36      **Vykunta, et al**       Prospective                  2011   19                   15     2.5 \[median\]
  36      **Vykunta, et al**       Prospective                  2011   19                   16     3 \[median\]
  37      **Giangennaro, et al**   Retrospective                2011   15                   13     12.4 \[mean\]
  38      **Roberto, et al**       Prospective                  2006   11                   7      5 \[mean\]

\*NR indicates not reported

[Table 2](#T0002){ref-type="table"} provides the mean and range of success, and weighted success rate and 95% CI of ketogenic diet. In retrospective studies, the weighted success rate of the patients who take the KD as a treatment option for epilepsy was 58.4% (95% confidence interval (95%CI)=48.7% -- 69.9%) at 3 months (n=336); 42.8% (95%CI =36.3% -- 50.3%) at 6 months (n=492), and 30.1% (95%CI = 24.3%-- 37.2%) at 12 months (n=387); in prospective studies, weighted success rate was 53.9% (95%CI 45.5% -- 63.8%) at 3 months (n=474); 53.2% (95%CI =44.0% -- 64.2%) at 6 months (n=321), and 55.0% (95%CI =45.9% -- 65.9%) at 12 months (n=347). In addition, weighted success rate for 1 month and 12 months in prospective study was 51.6% (95% CI =41.0% -- 65.1%) at 1 month (n=212), 58.5% (95% CI =48.1% -- 71.2%) at 12 months (n=278).

###### 

The therapeutic success of ketogenic diet with the corresponding ketogenic diet duration

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                            3M                              6 M                                    12 M                                                                                                                                                                                                                                            
  ------------------------- ------------------------------- -------------------------------------- -------------- ------------------------ ------------------------------ --------------------------------- -------------- ------------------------ ------------------------ ----------------------------- -------------- ------------------------ ------------------------
                            **Remain diet**                 24, 34, 35                             101            86.1\                    86.1\                          13, 24, 29, 34, 35                350            65.1\                    65.1 (55.2--77.0)\       28, 29, 34, 35                283            45.9\                    45.9 (37.3--56.5)\
                                                                                                                  (81.4--100.0)            (64.7--100.0)\                                                                  (58.1--76.9)             (Q=0.0004, *P*=1.0000)                                                (44.4--46.2)             (Q=0.0000, *P*=1.0000)
                                                                                                                                           (Q=0.0001, *P*=0.9990)                                                                                                                                                                                  

  **Retrospective study**   **Seizure free**                10, 12, 24, 32                         370            18.6\                    19.1 (14.8--24.8)\             13, 24, 29, 32                    426            16.2\                    18.1 (14.0--23.5)\       28, 29, 32                    359            11.1\                    12.1 (8.7--16.9)\
                                                                                                                  (15.7--34.9)             (Q=0.0003, *P*=1.000)                                                           (8.0--39.5)              (Q=0.0171, *P*=0.9998)                                                (6.5--17.1)              (Q=0.0046, *P*=0.9977)

  **\>90% Decrease**        10, 12, 32, 35                  240                                    26.3\          20.1 (15.2--26.7)\       32, 34, 35                     192                               16.1\          17.0 (11.6--25.0)\       32, 34, 35               192                           12.3\          15.0 (10.0--22.6)\       
                                                                                                   (16.4--53.8)   (Q=0.0048, *P*=0.9999)                                                                    (12.7--46.2)   (Q=0.0189, *P*=0.9905)                                                          (11.2--46.2)   (Q=0.0390, *P*=0.9807)   

                            **\>50% Decrease**              10, 12, 16, 24, 28, 32, 35             336            57.1\                    58.4 (48.7--69.9)\             13, 16, 24, 28, 29, 32 35         492            42.3\                    42.8 (36.3--50.3)\       28, 29, 32, 35, 37            387            28.9\                    30.1 (24.3--37.2)\
                                                                                                                  (20.0--100.0)            (Q=0.0089, *P*=1.0000)                                                          (19.2--61.5)             (Q=0.0676, *P*=1.0000)                                                (19.1--53.3)             (Q=0.0056, *P*=1.0000)

                            **Remain diet**                 14, 15, 23, 25, 31                     155            82.6\                    82.6\                          14, 15, 17, 21, 23, 25, 31        195            59.5\                    55.8 (46.8--66.5)\       2, 3, 5, 14, 15, 17, 31, 33   357            47.3\                    50.8 (42.1--61.3)\
                                                                                                                  (64.3--92.1)             (65.4--100.0)\                                                                  (37.5--85.0)             (Q=0.0092, *P*=1.0000)                                                (8.9--77.8)              (Q=0.1011, *P*=1.0000)
                                                                                                                                           (Q=0.0014, *P*=1.0000)                                                                                                                                                                                  

  **Prospective study**     **Seizure free**                3, 11, 20, 23, 25, 27, 30, 31, 36      343            16.6\                    17.7 (13.4--23.5)\             11, 15, 17, 20, 22, 23, 25, 31    347            23.3\                    26.9 (20.9--34.5)\       5, 11, 15, 17, 26, 33         466            15.9\                    17.7 (13.8--22.8)\
                                                                                                                  (3.3--28.6)              (Q=0.0089, *P*=1.0000)                                                          (3.3--30.6)              (Q=1.0223, *P*=0.9981)                                                (6.6--29.8)              (Q=0.1562, *P*=0.9995)

  **\>90% Decrease**        3, 11, 15, 18, 21, 25, 27, 30   339                                    16.5\          19.0 (14.2--25.4)\       3, 8, 11, 15, 17, 21, 22, 25   355                               16.3\          19.0 (14.3--25.2)\       3, 11, 15, 17, 26, 33    484                           16.1\          16.6 (13.1--21.2)\       
                                                                                                   (4.1--45.8)    (Q=0.9457, *P*=0.9986)                                                                    (5.0--34.0)    (Q=1.4530, *P*=0.9991)                                                          (7.4--35.0)    (Q=0.0879, *P*=0.9999)   

                            **\>50% Decrease**              2, 3, 11, 18, 20, 21, 23, 27, 30, 36   474            52.2\                    53.9 (45.5--63.8)\             2, 3, 8, 11, 15, 20, 21, 23, 25   321            52.3\                    53.2 (44.0--64.2)\       2, 3, 5, 11, 15, 33           347            53.6\                    55.0 (45.9--65.9)\
                                                                                                                  (10.0--66.7)             (Q=0.5554, *P*=1.0000)                                                          (22.2--65.0)             (Q=0.0798, *P*=1.000)                                                 (16.7--76.9)             (Q=0.0528, *P*=0.9999)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[Figs. 1](#F0001){ref-type="fig"} and [2](#F0002){ref-type="fig"} show the mean weighted therapeutic success rate of ketogenic diet in included retrospective and prospective study respectively.

![The mean weighted therapeutic success rate according to the duration of ketogenic diet in included retrospective study](IJPD-23-613-g001){#F0001}

![The mean weighted therapeutic success rate according to the duration of ketogenic diet in included prospective study](IJPD-23-613-g002){#F0002}

The Pearson\'s correlation coefficient (rho) of therapeutic success rate and age in ketogenic diet treatment is shown in [Figs. 3](#F0003){ref-type="fig"} and [4](#F0004){ref-type="fig"}. There was a negative correlation between therapeutic success rate and age at 3 months in retrospective study.

![The relationship of success rate of ketogenic diet and age at 3 month in included retrospective study](IJPD-23-613-g003){#F0003}

![The relationship of success rate of ketogenic diet and age at 3 month in included prospective study](IJPD-23-613-g004){#F0004}

Discussion {#S0007}
==========

Over the past 90 years since its introduction, the ketogenic diet has been shown to be extremely successful in existing studies. Although many studies have investigated the therapeutic success of ketogenic diet, a comprehensive and quantitative summary at different diet duration has been lacking. In most instances, however, results were fairly consistent in the direction of therapeutic success of ketogenic diet, even though studies differed in the estimation of effect extent. In this meta-analysis, compliance of patients was found to be decreased with the prolonged ketogenic diet duration. It is reported that the initial 3 months on the diet are typically considered a trial period. So the surveillance for the compliance should be carried out especially in the initial 3 months. Vining et al reported that 71% of patients with 50% seizure at 3 months could stay on the diet until the KD duration reached one year^\[[@CIT0042]\]^.

In this study, the therapeutic success of ketogenic diet was underscored using generic inverse variance method. This method is applied in meta-analysis when the results show no statistical heterogeneity. Each study estimate of the success rate is given a weight that is equal to the inverse of the variance of the effect estimate. Using this method, we found that in retrospective study, the success rate for patients who achieved therapeutic success (\>50% reduction in seizure frequency) were 58.4% at 3 month, 42.8% at 6 month, and 30.1% at 12 month respectively; and in prospective study, the success rates were 53.9% at 3 month, 53.2% at 6 month, and 55.0% at 12 month respectively. It is consistent with reported efficacy of ketogenic diet in controlling seizures that 56% had a \>50% reduction^\[[@CIT0043]\]^. When the ketogenic diet duration prolonged, the efficacy was found decreased. The decreased success rates may be related to the decrease of compliance. In addition, the influence of lost to follow up may be considered when in the designing period, especially for long observation period, and measures to control the loss of follow up may be carried out in retrospective studies. Therefore, the reported rates were lower in retrospective studies than in prospective studies at 12 months. Furthermore, we cannot calculate the efficacy for ketogenic diet considering the anti-epilepsy drugs treatment when taking the ketogenic diet, so there is a need for further studies to explore the interaction effect.

Guidance on the duration of dietary treatment is limited, and one study looked into the effect of the KD after its discontinuation, observing reduced benefit following cessation of treatment^\[[@CIT0010]\]^. Levy RG et al also point out the problem of poor persistence^\[[@CIT0001]\]^. The education level and care of the patient\'s family, the knowledge of epilepsy treatment, and the complicated recipe for daily diet treatment as well as the side effect of ketogenic diet result in poor compliance. Common side effects of the ketogenic diet are gastrointestinal complaints and unfavorable lipid profiles. But Kessler et al reported that side effects are usually transient and the most common reason for discontinuation of treatment is lack of effectiveness^\[[@CIT0044]\]^. Anyway, for the ketogenic diet to be clinically meaningful, persistence or compliance would be quiet important. And to improve therapeutic success of the ketogenic diet, some measures such as effectiveness evaluation, health education, supervision of compliance, awareness of epilepsy treatment, side effect minimizing, user-friendly recipe developing should be taken into consideration.

The ketogenic diet has been used with infants as young as 3 months and adults as old as 58 years. Although our analysis indicates the negative correlation between therapeutic success rate and age, this relationship was only found statistically significant at 3 month in retrospective study. There is a tendency for younger children to have higher success rate although this trend was not statistically significant. Ketogenic diet is currently used mainly for children who continue to have seizures despite treatment with antiepileptic drugs. Children\'s stomach capacity is small and the liver glycogen storage quantity is limited, so the energy storage level of children is lower than that of adults. Due to the higher energy storage level of adults and comparable stable blood glucose levels, the adult ketogenic diet practice is not as successful as in children. The results on less than 20% seizure free after treating with ketogenic diet for epileptic patients may be related to the age factor.

Conclusion {#S0008}
==========

This meta-analysis provides formal statistical support for the efficacy of the ketogenic diet in the treatment of epileptic patients. There is a tendency for younger age patients to have higher success rate although this trend was not statistically significant. It shows the need for further research on interaction effect considering both ketogenic diet and anti-epilepsy drugs.
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